PHA-680632 ezolid (S)-Rolipram

(S)-Rolipram

Smiles: C[C@@H]1CC[C@H](C[C@H]1O)NC1=NC(NC(C)(C)C)=NC=C1C(N)=O

BIBW2992 is currently undergoing Phase III clinical trials for non-small cell lung carcinoma (NSCLC) and breast cancer

with only minor body weight changes

is a Th2 cytokine inhibitor which is used as an antiallergic drug

PHA-680632 ezolid (S)-RolipramPHA 680632 is a is potent inhibitor of Aurora A, Aurora B and Aurora C with IC50 of 27 nM, 135 nM and 120 nM, respectively. PHA 680632 is also the first representative of a new class of Aurora inhibitors with a high potential for further development as an anticancer therapeutic. PHA 680632 is active on a wide range of cancer cell lines and shows significant tumor growth inhibition in different animal tumor models at well tolerated doses. Product